Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

van Campenhout, M.; Brouwer, W.; van Oord, G.; Xie, Q.; Zhang, Q.; Zhang, N.; Guo, S.; Tabak, Ömer; Streinu-Cercel, A.; Wang, J.; Pas, S.; Sonneveld, M.; de Knegt, R.; Boonstra, A.; Hansen, B.; Janssen, H.

doi:10.1016/j.cmi.2016.02.002

Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

Copy For Citation

van Campenhout M. J. H., Brouwer W. P., van Oord G. W., Xie Q., Zhang Q., Zhang N., ...More

CLINICAL MICROBIOLOGY AND INFECTION, vol.22, no.6, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 22 Issue: 6
Publication Date: 2016
Doi Number: 10.1016/j.cmi.2016.02.002
Journal Name: CLINICAL MICROBIOLOGY AND INFECTION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Istanbul University Affiliated: Yes

Abstract

Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.